Will appetite-suppressing drugs hurt the sugar industry? Executives from Walmart warned that Ozempic and Zepbound "are impacting food sales," reports Bloomberg, "and multiple analyst surveys have showed that less-hungry customers are spending fewer dollars at grocery stores and restaurants." The drugs, which cut cravings, will result in a decline in calorie consumption in the US of 1.5% to 2.5% by 2035, with a drop of as much as 5% in the consumption of sweets such as baked goods, confectionery and soda, Morgan Stanley analysts including Pamela Kaufman said in a report last month. Morgan Stanley forecast about a 10th of the US population will be on the so-called GLP-1 medications — originally designed to treat diabetes but being used by many as a powerful weight-loss tool — by 2035... Even with tight supplies and sky-high prices limiting uptake of the medications, sales of GLP-1 drugs for both obesity and diabetes already exceeded $19 billion in 2023. The global obesity market alone could top $100 billion by the end of the decade, Goldman Sachs Group Inc. estimates, while Bloomberg Intelligence forecasts $80 billion of sales.

More than 60% of US consumers taking the drugs said they had cut back on sweet treats like candy, ice cream and baked goods, and many said they had either significantly — or entirely — stopped eating those products, according to Morgan Stanley.

"Chinese scientists develop cure for diabetes," reads the headline from the world's second-most widely read English-language newspaper. ("Insulin patient becomes medicine-free in just 3 months.")

The researchers' results were published earlier in May in Cell Discovery, and are now getting some serious scrutiny from the press. The Economic Times cites a University of British Columbia professor's assessment that the study "represents an important advance in the field of cell therapy for diabetes," in an article calling it a "breakthrough" that "marks a significant advancement in cell therapy for diabetes." Chinese scientists have successfully cured a patient's diabetes using a groundbreaking cell therapy... According to a South China Morning Post report, the patient underwent the cell transplant in July 2021. Remarkably, within eleven weeks, he no longer required external insulin. Over the next year, he gradually reduced and ultimately stopped taking oral medication for blood sugar control. "Follow-up examinations showed that the patient's pancreatic islet function was effectively restored," said Yin, one of the lead researchers. The patient has now been insulin-free for 33 months... The new therapy involves programming the patient's peripheral blood mononuclear cells, transforming them into "seed cells" to recreate pancreatic islet tissue in an artificial environment.
Their article calls it "a significant medical milestone" — noting that 140 million people in China have diabetes (according to figures from the International Diabetes Federation).

Thanks to long-time Slashdot reader AmiMoJo for sharing the news.

Long before people develop dementia, they often begin falling behind on mortgage payments, credit card bills and other financial obligations, new research shows. The New York Times: A team of economists and medical experts at the Federal Reserve Bank of New York and Georgetown University combined Medicare records with data from Equifax, the credit bureau, to study how people's borrowing behavior changed [PDF] in the years before and after a diagnosis of Alzheimer's or a similar disorder. What they found was striking: Credit scores among people who later develop dementia begin falling sharply long before their disease is formally identified. A year before diagnosis, these people were 17.2 percent more likely to be delinquent on their mortgage payments than before the onset of the disease, and 34.3 percent more likely to be delinquent on their credit card bills. The issues start even earlier: The study finds evidence of people falling behind on their debts five years before diagnosis.

"The results are striking in both their clarity and their consistency," said Carole Roan Gresenz, a Georgetown University economist who was one of the study's authors. Credit scores and delinquencies, she said, "consistently worsen over time as diagnosis approaches, and so it literally mirrors the changes in cognitive decline that we're observing." The research adds to a growing body of work documenting what many Alzheimer's patients and their families already know: Decision-making, including on financial matters, can begin to deteriorate long before a diagnosis is made or even suspected. People who are starting to experience cognitive decline may miss payments, make impulsive purchases or put money into risky investments they would not have considered before the disease.

Private-equity investors have poured billions into healthcare but often game the system, hurting both doctors and patients. From a report: Consolidation is as American as apple pie. When a business gets bigger, it forces mom-and-pop players out of the market, but it can boost profits and bring down costs, too. Think about the pros and cons of Walmart and "Every Day Low Prices." In a complex, multitrillion-dollar system like America's healthcare market, though, that principle has turned into a harmful arms race that has helped drive prices increasingly higher without improving care. Years of dealmaking has led to sprawling hospital systems, vertically integrated health insurance companies, and highly concentrated private equity-owned practices resulting in diminished competition and even the closure of vital health facilities. As this three-part Heard on the Street series will show, the rich rewards and lax oversight ultimately create pain for both patients and the doctors who treat them. Belatedly, state and federal regulators and lawmakers are zeroing in on consolidation, creating uncertainty for the investors who have long profited from the healthcare merger boom.

Consider the impact of massive private-equity investment in medical practices. When a patient with employer-based insurance goes under for surgery, the anesthesiologist's fee is supposed to be determined by market forces. But what happens if one firm quietly buys out several anesthesiologists in the same city and then hikes the price of the procedure? Such a scheme was allegedly implemented by the private-equity firm Welsh, Carson, Anderson & Stowe and the company it created in 2012, U.S. Anesthesia Partners, according to a Federal Trade Commission lawsuit filed last year. It started by buying the largest practice in Houston and then making three further acquisitions, eventually expanding into other cities throughout the state of Texas. In each location, the lawsuit alleges, USAP pursued an aggressive strategy of eliminating competitors by either acquiring them or conspiring with them to weaken competition. As one insurance executive put it in the FTC lawsuit, USAP and Welsh Carson used acquisitions to "take the highest rate of all ... and then peanut butter spread that across the entire state of Texas." In May, U.S. District Judge Kenneth Hoyt dismissed the FTC's unusual step of charging the private-equity investor, Welsh Carson, but allowed the case against USAP to proceed.

"About 1 in 9 children in the U.S., between the ages of 3 and 17, have been diagnosed with ADHD," reports NPR: That's according to a new report from the Centers for Disease Control and Prevention that calls attention-deficit/hyperactivity disorder an "expanding public health concern."

Researchers found that in 2022, 7.1 million kids and adolescents in the U.S. had received an ADHD diagnosis — a million more children than in 2016. That jump in diagnoses was not surprising, given that the data was collected during the pandemic, says Melissa Danielson, a statistician with the CDC's National Center on Birth Defects and Developmental Disabilities and the study's lead author. She notes that other studies have found that many children experienced heightened stress, depression and anxiety during the pandemic. "A lot of those diagnoses... might have been the result of a child being assessed for a different diagnosis, something like anxiety or depression, and their clinician identifying that the child also had ADHD," Danielson says. The increase in diagnoses also comes amid growing awareness of ADHD — and the different ways that it can manifest in children...

The study, which appears in the Journal of Clinical Child & Adolescent Psychology, was based on data from the National Survey of Children's Health, which gathers detailed information from parents.

UPI reports that the British government covered up "a multi-decade tainted blood scandal, leading to thousands of related deaths, a report published Monday found." Britain's National Health Service allowed blood tainted with HIV and Hepatitis to be used on patients without their knowledge, leading to 3,000 deaths and more than 30,000 infections, according to the 2,527-page final report by Justice Brian Justice Langstaff, a former judge on the High Court of England and Wales. Langstaff oversaw a five-year investigation into the use of tainted blood and blood products in Britain's healthcare system between 1970 and 1991. The report blames multiple administrations over the time period for knowingly exposing victims to unacceptable risks...

In several cases, health officials lied about the risks to patients... The NHS also gave patients false reassurances, an attempt to "save face," failing victims "not once but repeatedly...." The situation could "largely, though not entirely, have been avoided," Langstaff found...

The British government on Monday began operating a support phone line for people and their families affected by the tainted blood scandal.
The article notes that Langstaff described the coverup as "subtle" but "pervasive" and "chilling in its implications...

"To save face and to save expense, there has been a hiding of much of the truth."

Thanks to long-time Slashdot reader schwit1 for sharing the article.

An anonymous reader quotes a report from NPR: Hospital staff are forced to write notes by hand and deliver orders for tests and prescriptions in person in the ongoing fallout from a recent ransomware attack at the national health system Ascension. Ascension is one of the largest health systems in the United States, with some 140 hospitals located across 19 states and D.C. A spokesperson said in a statement that "unusual activity" was first detected on multiple technology network systems Ascension uses on Wednesday, May 8. Later, representatives confirmed that some of Ascension's electronic health records systems had been affected, along with systems used "to order certain tests, procedures and medications."

Some phone capabilities have also been offline, and patients have been unable to access portals used to view medical records and get in touch with their doctors. Due to these interruptions, hospital staff had to shift to "manual and paper based" processes. "Our care teams are trained for these kinds of disruptions and have initiated procedures to ensure patient care delivery continues to be safe and as minimally impacted as possible," an Ascension spokesperson said in a May 8 statement. Kris Fuentes, who works in the neonatal intensive care unit at Ascension Seton Medical Center in Austin, said she remembers when paper charting was the norm. But after so many years of relying on digital systems, she said her hospital wasn't ready to make such an abrupt shift. "It's kind of like we went back 20 years, but not even with the tools we had then," Fuentes said. "Our workflow has just been really unorganized, chaotic and at times, scary."

Fuentes said orders for medication, labs and imaging are being handwritten and then distributed by hand to various departments, whereas typically these requests are quickly accessed via computer. A lack of safety checks with these backup methods has introduced errors, she said, and every task is taking longer to complete. "Medications are taking longer to get to patients, lab results are taking longer to get back," she said. "Doctors need the lab results, often, to decide the next treatment plan, but if there's a delay in access to the labs, there's a delay in access to the care that they order." As of Tuesday, Ascension still had no timeline for when the issues might be resolved, and reported that it continued to work with "industry-leading cybersecurity experts" to investigate the ransomware attack and restore affected systems. The FBI and Cybersecurity and Infrastructure Security Agency are also involved in the investigation. "While Ascension facilities remain open, a health system representative said on May 9 that in some cases, emergency patients were being triaged to different hospitals, and some non-emergent appointments and procedures were postponed," reports NPR. "Certain Ascension pharmacies are not operational, and patients are being asked to bring in prescription bottles or numbers."

"Individuals who are enrolled in Ascension health insurance plans are being directed to mail in monthly payments while the electronic payment system is down."

Hybrid and electric cars are more likely to hit pedestrians than petrol or diesel vehicles, due to their quieter engines that make them harder for pedestrians to hear. Other contributing factors include the tendency for drivers of electric cars to be younger and less experienced, and the vehicles' heavier weight and swift acceleration, increasing stopping distances. The Guardian reports: Data from 32 billion miles of battery-powered car travel and 3 trillion miles of petrol and diesel car trips showed that mile-for-mile electric and hybrid cars were twice as likely to hit pedestrians than fossil fuel-powered cars, and three times more likely to do so in urban areas. "Electric cars are a hazard to pedestrians because they are less likely to be heard than petrol or diesel cars," said Phil Edwards, first author on the study and professor of epidemiology and statistics at the London School of Hygiene & Tropical Medicine. "The government needs to mitigate these risks if they are going to phase out the sale of petrol and diesel cars." "If you're moving to an electric car, remember it's a new kind of vehicle," Edwards added. "They are much quieter than the old-fashioned cars, and pedestrians have learned to navigate roads by listening for traffic. Drivers of these vehicles need to be extra cautious."

Most vehicles on the road are petrol or diesel and these were involved in three-quarters of pedestrian collisions. But for the same distance travelled, battery-powered cars were more dangerous. The average annual pedestrian casualty rate per 100m miles travelled was 5.16 for electric and hybrid cars compared with 2.4 for petrol and diesel cars, according to the study in the Journal of Epidemiology and Community Health. In rural settings, battery-powered cars were no more dangerous than petrol or diesel, but in towns and cities they were three times more likely to collide with pedestrians, the researchers found. Since July 2019, all new hybrid and electric vehicles sold in Europe have been required to have an acoustic vehicle alerting system that emits sound when the car is travelling slowly, but there are hundreds of thousands of electric cars on the road without the devices. "If government made sure these systems were installed in all electric vehicles and retrofitted them to older electric cars, that would be a good start," Edwards said, adding that the Green Cross Code also "probably needs updating."

The FDA has approved Neuralink to implant its brain chip in a second patient. According to the Wall Street Journal, the company also outlined fixes to an electrode problem that caused its chip to detach from the first patient's brain. They were unharmed and could still control a computer mouse using their thoughts. Axios reports: Neuralink, which is owned by Elon Musk, said it is seeking applications for another patient with quadriplegia to test if the device can allow a person to do tasks like control a phone and computer. It outlined fixes that included embedding some of the device's wiring deeper into the brain, the Wall Street Journal reported, citing a document and a person familiar with the company.

Neuralink rival Synchron is preparing a large-scale clinical trial with an eye toward seeking commercial approval of its implant. Mass General Brigham has also launched a collaborative effort with stakeholders and the FDA to accelerate the development of the implanted devices.

An anonymous reader quotes a report from Medical Xpress: A team of medical researchers at the National Children's Medical Center, Children's Hospital, Fudan University, in China, has developed a technique to freeze and thaw brain tissue without causing damage. In their study, published in the journal Cell Reports Methods, the group tested bathing brain organoid tissue in candidate chemicals before freezing them using liquid nitrogen. [...] The work involved dipping or soaking brain organoids (brain tissue grown from stem cells) in candidate compounds and then freezing and thawing them to see how they fared. After many attempts, they found one combination of solutions that worked best -- a mix of ethylene glycol, methylcellulose DMSO and Y27632. They named the solution mix MEDY.

The research team then tested MEDY under a variety of conditions to see how well it prevented damage from freezing. The conditions involved changing variables, such as the age of the organoids prior to freezing and how long they were soaked in a MEDY solution. They then allowed the organoids to resume growing after they were thawed for up to 150 days. The researchers found little difference between organoids that had been frozen and those that had not -- even those that had been frozen for as long as 18 months. As a final test, the research team used their technique on a sample of brain tissue obtained from a live human patient and found that it worked just as well.

An anonymous reader shares a report: Hims & Hers Health, one of the online pharmacies that got its start prescribing dick pills, is now offering knockoff versions of GLP-1 weight loss drugs. Hims & Hers says it will offer drugs that mimic Ozempic and Wegovy, the active ingredient of which is semaglutide. The copycat versions are made by compounding pharmacies. The formulations aren't the same as the FDA-approved versions of the drug and haven't been directly evaluated by the FDA, either. But they're cheaper than the real thing: $199 a month, compared to the branded version, which can cost more than $1,000 a month without insurance.

Compounding pharmacies can make knockoff versions of branded drugs when they are in shortage, as the GLP-1 drugs -- prescribed for diabetes and weight loss -- currently are. The FDA has already received reports of adverse events for compounded versions of semaglutide. Hims & Hers says it "conducted extensive research for over a year" into finding a supplier, but does not name the one it chose to partner with. "Over the last year, we have grown in our conviction -- based on our medical experts' evaluation and the strength of our infrastructure -- that if done properly, compounded GLP-1s are safe and effective," the company said in its statement.

An anonymous reader quotes a report from The Guardian: Proteins in the blood could warn people of cancer more than seven years before it is diagnosed, according to research [published in the journal Nature Communications]. Scientists at the University of Oxford studied blood samples from more than 44,000 people in the UK Biobank, including over 4,900 people who subsequently had a cancer diagnosis. They compared the proteins of people who did and did not go on to be diagnosed with cancer and identified 618 proteins linked to 19 types of cancer, including colon, lung, non-Hodgkin lymphoma and liver.

The study, funded by Cancer Research UK and published in Nature Communications, also found 107 proteins associated with cancers diagnosed more than seven years after the patient's blood sample was collected and 182 proteins that were strongly associated with a cancer diagnosis within three years. The authors concluded that some of these proteins could be used to detect cancer much earlier and potentially provide new treatment options, though further research was needed.

An anonymous reader quotes a report from CBS News: Richard "Rick" Slayman, the first human to receive a genetically modified pig kidney transplant, has died almost two months after the procedure. Slayman, who had end-stage kidney disease, underwent the transplant in March at Massachusetts General Hospital in Boston at age 62. The hospital said in a statement on Saturday that there was "no indication" that his death was the result of the transplant. The transplant surgeon had said he hoped the transplant would function for at least two years.

"The Mass General transplant team is deeply saddened at the sudden passing of Mr. Rick Slayman," read the hospital statement. "Mr. Slayman will forever be seen as a beacon of hope to countless transplant patients worldwide and we are deeply grateful for his trust and willingness to advance the field of xenotransplantation." The surgery was a milestone for the field of xenotransplantation -- the transplant of organs from one species to another -- as a way to alleviate the organ shortage for people who need transplants. The effort to genetically modify animal organs is in hopes that the human body will not reject the foreign tissue. NPR notes that there are more than 100,000 people in the U.S. on the waitlist for organs.

Brian Shelton's type 1 diabetes was treated with an infusion of insulin-producing pancreas cells (grown from stem cells). In 2021, the New York Times reported: Now his body automatically controls its insulin and blood sugar levels. Shelton, now 64, may be the first person cured of the disease with a new treatment that has experts daring to hope that help may be coming for many of the 1.5 million Americans suffering from Type 1 diabetes. "It's a whole new life," Shelton said. Diabetes experts were astonished but urged caution. The study is continuing and will take five years, involving 17 people with Type 1 diabetes.
"By fall 2023, three patients, including Shelton, had achieved insulin independence by day 180 post-transplant," MedScape reported (in January of 2024): In the phase 1/2 study, 14 patients with type 1 diabetes and impaired hypoglycemia awareness or recurrent hypoglycemia received portal vein infusions of VX-880 [Vertex Pharmaceutical's pancreatic islet cell replacement therapy] along with standard immunosuppression. As of the last data cut, all 14 patients demonstrated islet cell engraftment and production of endogenous insulin. After more than 90 days of follow-up, 13 of the patients have achieved A1c levels < 7% without using exogenous insulin.
Brian Shelton and another patient died, and while Vertex says their deaths were unrelated to the treatment, they have "placed the study on a protocol-specified pause, pending review of the totality of the data by the independent data monitoring committee and global regulators." (MedScape adds that Vertex "is continuing with a phase 1/2 clinical trial of a different product, VX-264, which encapsulates the same VX-880 cells in a device designed to eliminate the need for immunosuppression.")

And meanwhile, a new study in China (again using stem cell-derived islet tissue) has provided "encouraging evidence that islet tissue replacement is an effective cure for diabetic patients," the researchers wrote in Nature. The treatment was administered to 59-year-old, type-2 diabetic.

"Marked changes in the patient's glycemic control were observed as early as week 2," the researchers write, and after week 32, the patient's Time In Tight Range (TITR) "had readily reached 99% and was maintained thereafter."

Thanks to long-time Slashdot reader hackingbear for sharing the news.

An anonymous reader quotes a report from Interesting Engineering: Imagine exploring the intricate world within a single cubic millimeter of human brain tissue. It might seem insignificant, but within that tiny space lies a universe of complexity -- 57,000 individual cells, 230 millimeters of blood vessels, and a staggering 150 million synapses, the junctions where neurons communicate. All this information translates to a mind-boggling 1,400 terabytes of data. That's the kind of groundbreaking achievement researchers from Harvard and Google have just accomplished.

Leading the charge at Harvard is Professor Jeff Lichtman, a renowned expert in brain structure. Partnering with Google AI, Lichtman's team has co-created the most detailed 3D reconstruction of a human brain fragment to date. This intricate map, published in Science, offers an unprecedented view of the human temporal cortex, the region responsible for memory and other higher functions. Envision a piece of brain tissue roughly half the size of a rice grain but magnified to reveal every cell and its web of neural connections in vivid detail. This remarkable feat is the culmination of nearly a decade of collaboration between Harvard and Google. Lichtman's expertise in electron microscopy imaging is combined with Google's cutting-edge AI algorithms. [...]

The newly published map in Science reveals previously unseen details of brain structure. One such discovery is a rare but powerful set of axons, each connected by up to 50 synapses, potentially influencing a significant number of neighboring neurons. The team also encountered unexpected structures, like a small number of axons forming intricate whorls. Since the sample came from a patient with epilepsy, it's unclear if these formations are specific to the condition or simply uncommon occurrences.

Ancient Slashdot reader jd shares a report from The Guardian: Neuralink's first attempt at implanting its chip in a human being's skull hit an unexpected setback after the device began to detach from the patient's brain, the company revealed on Wednesday. The patient, Noland Arbaugh, underwent surgery in February to attach a Neuralink chip to his brain, but the device's functionality began to decrease within the month after his implant. Some of the device's threads, which connect the miniature computer to the brain, had begun to retract. Neuralink did not disclose why the device partly retracted from Arbaugh's brain, but stated in a blog post that its engineers had refined the implant and restored functionality.

The decreased capabilities did not appear to endanger Arbaugh, and he could still use the implant to play a game of chess on a computer using his thoughts, according to the Wall Street Journal, which first broke the news of the issue with the chip. The possibility of removing the implant was considered after the detachment came to light, the Journal reported. [...] Arbaugh praised the implant during a demonstration in March and said that it had "already changed his life," while also stating that it had not been perfect and they "have run into some issues."

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic. From a report: The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe. "As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied. According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.

Pam Belluck reports via the New York Times: Scientists are proposing a new way of understanding the genetics of Alzheimer's that would mean that up to a fifth of patients would be considered to have a genetically caused form of the disease. Currently, the vast majority of Alzheimer's cases do not have a clearly identified cause. The new designation, proposed in a study published Monday, could broaden the scope of efforts to develop treatments, including gene therapy, and affect the design of clinical trials. It could also mean that hundreds of thousands of people in the United States alone could, if they chose, receive a diagnosis of Alzheimer's before developing any symptoms of cognitive decline, although there currently are no treatments for people at that stage. The new classification would make this type of Alzheimer's one of the most common genetic disorders in the world, medical experts said.

"This reconceptualization that we're proposing affects not a small minority of people," said Dr. Juan Fortea, an author of the study and the director of the Sant Pau Memory Unit in Barcelona, Spain. "Sometimes we say that we don't know the cause of Alzheimer's disease," but, he said, this would mean that about 15 to 20 percent of cases "can be tracked back to a cause, and the cause is in the genes." The idea involves a gene variant called APOE4. Scientists have long known that inheriting one copy of the variant increases the risk of developing Alzheimer's, and that people with two copies, inherited from each parent, have vastly increased risk.

The new study, published in the journal Nature Medicine, analyzed data from over 500 people with two copies of APOE4, a significantly larger pool than in previous studies. The researchers found that almost all of those patients developed the biological pathology of Alzheimer's, and the authors say that two copies of APOE4 should now be considered a cause of Alzheimer's -- not simply a risk factor. The patients also developed Alzheimer's pathology relatively young, the study found. By age 55, over 95 percent had biological markers associated with the disease. By 65, almost all had abnormal levels of a protein called amyloid that forms plaques in the brain, a hallmark of Alzheimer's. And many started developing symptoms of cognitive decline at age 65, younger than most people without the APOE4 variant.

In a first for "digital health technology," the Apple Watch's atrial fibrillation (AFib) history feature has been approved by the FDA to join the FDA's Medical Device Development Tools (MDDT) program. This means the wearable is now usable in clinical studies. The Verge reports: The FDA announcement describes using it as a noninvasive way to collect the data both before and after treatment: "Designed to be used as a biomarker test to help evaluate estimates of AFib burden as a secondary effectiveness endpoint within clinical studies intended to evaluate the safety and effectiveness of cardiac ablation devices to treat."

An anonymous reader quotes a report from Techdirt: Last week, hundreds of nurses protested the implementation of sloppy AI into hospital systems in front of Kaiser Permanente. Their primary concern: that systems incapable of empathy are being integrated into an already dysfunctional sector without much thought toward patient care: "No computer, no AI can replace a human touch," said Amy Grewal, a registered nurse. "It cannot hold your loved one's hand. You cannot teach a computer how to have empathy."

There are certainly roles automation can play in easing strain on a sector full of burnout after COVID, particularly when it comes to administrative tasks. The concern, as with other industries dominated by executives with poor judgement, is that this is being used as a justification by for-profit hospital systems to cut corners further. From a National Nurses United blog post (spotted by 404 Media): "Nurses are not against scientific or technological advancement, but we will not accept algorithms replacing the expertise, experience, holistic, and hands-on approach we bring to patient care," they added.

Kaiser Permanente, for its part, insists it's simply leveraging "state-of-the-art tools and technologies that support our mission of providing high-quality, affordable health care to best meet our members' and patients' needs." The company claims its "Advance Alert" AI monitoring system -- which algorithmically analyzes patient data every hour -- has the potential to save upwards of 500 lives a year. The problem is that healthcare giants' primary obligation no longer appears to reside with patients, but with their financial results. And, that's even true in non-profit healthcare providers. That is seen in the form of cut corners, worse service, and an assault on already over-taxed labor via lower pay and higher workload (curiously, it never seems to impact outsized high-level executive compensation).